MXCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MXCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
MaxCyte has the Growth Rank of 7.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Medical Devices subindustry, MaxCyte's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Growth Rank distribution charts can be found below:
* The bar in red indicates where MaxCyte's Growth Rank falls into.
Thank you for viewing the detailed overview of MaxCyte's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Stanley C Erck | director | 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878 |
John Joseph Johnston | director | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Thomas M. Ross | officer: EVP, Global Sales | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Maher Masoud | officer: EVP and General Counsel | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Douglas Doerfler | director, officer: President and CEO | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Richard Douglas | director | ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
Douglas J Swirsky | officer: Chief Financial Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850 |
Patrick J Balthrop | director | C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850 |
Casdin Partners Master Fund, L.p. | 10 percent owner | WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001 |
Cenk Sumen | officer: Chief Scientific Officer | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Amanda Louise Murphy | officer: Chief Financial Officer | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Ron Holtz | officer: SVP and CAO | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Yasir B. Al-wakeel | director | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Art Mandell | director | C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
William W Brooke | director | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
From GuruFocus
By Marketwired • 10-31-2024
By GuruFocus Research • 02-08-2024
By GuruFocus News • 11-07-2024
By Marketwired • 11-13-2024
By Marketwired • 05-29-2024
By GuruFocus Research • 08-06-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus News • 11-14-2024
By GuruFocus News • 10-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.